eptinezumab
Selected indexed studies
- Eptinezumab. (, 2006) [PMID:32697467]
- Eptinezumab: First Approval. (Drugs, 2020) [PMID:32266704]
- Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. (Neurology, 2020) [PMID:32209650]
_Worker-drafted node — pending editorial review._
Connections
eptinezumab is a side effect of
Sources
- Eptinezumab. (2006) pubmed
- Eptinezumab: First Approval. (2020) pubmed
- Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. (2020) pubmed
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). (2020) pubmed
- Eptinezumab for the treatment of migraine. (2019) pubmed
- Eptinezumab for the treatment of migraine. (2021) pubmed
- PMID:40080618 (2023) pubmed
- Eptinezumab. (2012) pubmed
- Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. (2022) pubmed
- Eptinezumab for the preventive treatment of migraine. (2021) pubmed